secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001829126-24-008141
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals appoints new CEO Chay Weei Jye and changes auditor to Enrome LLP
--------------------------------------------------------------------------------

- Appointed Chay Weei Jye as CEO effective Dec 2, 2024; previously CTO of Zchwantech.
- Audit committee selected Enrome LLP as independent auditor for FY 2024, subject to engagement letter.
- Neither company nor anyone on its behalf consulted Enrome on accounting principles or disagreements prior to engagement.
- Mr. Chay, age 52, holds a Bachelor of Computer Science from Universiti Putra Malaysia.
- No family relationships or arrangements with other persons in selection; no reportable events with prior auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912624008141/0001829126-24-008141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912624008141/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-008141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer